Señales en vivo de GMAB.CO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 10:59):

Stats
Volumen de hoy	93 580.00
Volumen promedio	128 106
Capitalización de mercado	131.06B
EPS	DKK20.18 ( 2024-05-02 )
Próxima fecha de ganancias	( DKK22.15 ) 2024-07-31
Last Dividend	DKK0 ( N/A )
Next Dividend	DKK0 ( N/A )
P/E	24.25
ATR14	DKK1.303 (0.06%)

Volumen Correlación

Largo: 0.17 (neutral)

Corto: 0.81 (strong)

Signal:(58.5) Same movement expected

Genmab A/S Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genmab A/S Correlación - Moneda/Commodity

-0.49
( neutral )

-0.31
( neutral )

-0.01
( neutral )

0.31
( neutral )

-0.04
( neutral )

0.68
( moderate )

Genmab A/S Finanzas

Annual	2023
Ingresos:	DKK16.47B
Beneficio Bruto:	DKK16.25B (98.63 %)
EPS:	DKK66.64

FY	2023
Ingresos:	DKK16.47B
Beneficio Bruto:	DKK16.25B (98.63 %)
EPS:	DKK66.64

FY	2022
Ingresos:	DKK14.60B
Beneficio Bruto:	DKK14.60B (100.00 %)
EPS:	DKK83.38

FY	2021
Ingresos:	DKK8.48B
Beneficio Bruto:	DKK0.00 (0.00 %)
EPS:	DKK46.00

Financial Reports:

No articles found.

Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.